Auxilium Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Malvern, Pennsylvania. Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to urologists, endocrinologists, orthopedists and select primary care physicians. The Company’s product, Testim, is a topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism. Hypogonadism is defined as reduced or absent secretion of testosterone which can lead to symptoms such as low energy, loss of libido, adverse changes in body composition, irritability and poor concentration. The product pipeline of the Company includes XIAFLEX (clostridial collagenase for injection) for the treatment of Dupuytren’s contracture (Dupuytren’s), XIAFLEX for the treatment of Peyronie’s disease (Peyronie’s), XIAFLEX for the treatment of Adhesive Capsulitis (frozen shoulder syndrome), AA4010, treatment for overactive bladder using the transmucosal film delivery system and fentanyl pain product using the transmucosal film delivery system.

China Sky One Medical, Inc. is engaged in the development, manufacture, marketing and sale of over-the-counter, branded nutritional supplements and over-the-counter plant and herb based pharmaceutical and medicinal products. Its principal products are external use Traditional Chinese Herbal Remedies/Medicines (TCM). The Company is also an integrated manufacturer, marketer and distributor of external use Chinese medicine products sold primarily in China and through Chinese domestic pharmaceutical chains. The Company sells both its own manufactured products, as well as medicinal and pharmaceutical products manufactured by others in China. All of its business is conducted through its wholly owned subsidiary, American California Pharmaceutical Group, Inc. (ACPG) which, in turn, wholly owns Harbin Tian Di Ren Medical Science and Technology Company (TDR). On April 3, 2008, TDR completed its acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.

Eurand N.V. company was formerly known as Eurand B.V. Eurand N.V. was incorporated in 1984 and is based in Amsterdam, the Netherlands. Eurand N.V., a specialty pharmaceutical company, develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. The company develops these products based on its proprietary customized release technologies used to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; Tastemasking/ODTs technologies to increase patient compliance through more convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technologies to improve drug absorption; and drug conjugation technologies to extend drug half-life and to target specific organs or other biological targets, such as tumors. Its technologies are used for applications in drug products used for various therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition, and respiratory.Eurand company offers EUR-1037, as an over-the-counter sleep-aid; EUR-1025, an oral formulation of ondansetron, an anti-emetic prescribed to prevent nausea and vomiting; and EUR-1073, an enteric coated, controlled release formulation of beclomethasone diproprionate for the treatment of inflammatory bowel disease. It products also include Zentase, also known as EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency, which has completed Phase III clinical trials; Amrix, a sustained release formulation of cyclobenzaprine hydrochloride, used as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions; and products and services to the cystic fibrosis community.

454 Life Sciences company has developed a computer-controlled instrument and related software that enable scientists to analyze whole genomes in one fell swoop, rather than a few hundred genes at a time. Parent company Roche Diagnostics distributes 454 Life Sciences' Genome Sequencing Systems to clinical laboratories, research departments of drugmakers, and other customers worldwide. Research fields include cancer and infectious disease, drug discovery, and paleontology. The company's 454 Sequencing Center provides sequencing services directly.

Aradigm Corporation company was founded in 1991 and is based in Hayward, California. Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. Aradigm company's activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease (COPD), inhalation anthrax infections, and smoking cessation. Its proprietary product candidates under development include ARD-3100 under phase II clinical trial for the treatment of cystic fibrosis; ARD-3150 under phase II clinical trial for the treatment of bronchiectasis; ARD-1600 under phase I clinical trial for the treatment of tobacco smoking cessation; and ARD-1100, a preclinical product for the treatment of inhalation anthrax indications. Aradigm company's collaborative product candidates comprise ARD-1550, a phase II product and ARD-1500, a preclinical stage product for the treatment of pulmonary arterial hypertension; and ARD-1700, a preclinical stage product for the treatment of asthma and COPD. Aradigm Corporation has a collaboration agreement with CyDex Pharmaceuticals, Inc. for the development and commercialization of products to deliver inhaled corticosteroids, anticholinergics, and beta-2 agonists for the treatment of asthma and COPD.

BD Biosciences company, a division of medical equipment firm Becton, Dickinson (BD), provides research supplies to the life sciences market. Its primary Cell Analysis unit offers cell imaging devices, flow cytometers (for cell sorting), and chemical reagents and antibodies (proteins) for cellular analysis. The Discovery Labware unit makes basic lab supplies including pipettes, tubes, and cell culture kits. In addition to scientific researchers and drug developers, BD Biosciences counts among its customers blood banks, hospitals, and clinical labs. The company sells its goods around the world through direct and indirect marketing reps and independent distributors.

Labcyte Inc. company sells automated dispensing systems, plate assemblers, microplates, and labware supplies. Labcyte's products are built around a liquid management technology it calls Acoustic Droplet Ejection (ADE) which uses sound energy to move miniscule bits of liquid without any physical contact during transfer. ADE is useful where cross-contamination would compromise quality or data and it reduces the waste created by disposable liquid handling supplies. Labcyte's customers include pharmaceutical and biomedical research labs. The company has expanded distribution of its products into Europe and Asia.

A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company’s primary focus is on its lead product candidate, APF530, which completed a pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the year ended December 31, 2008. APF530 is designed to prevent CINV for at least five days and contains granisetron, a drug approved for the prevention of CINV. In addition to its lead drug candidate, A.P. Pharma has a pipeline of other product candidates that use its Biochronomer technology. One of these, APF112, incorporates the local anesthetic, mepivacaine. It is designed to provide up to 36 hours of post-surgical pain relief and to minimize the use of morphine-like drugs, or opiates, which are used in post-surgical pain management.

Insmed Incorporated Company was founded in 1999 and is headquartered in Richmond, Virginia. Insmed Incorporated, a development stage company, engages in the development of recombinant protein drug. The company's primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions, as well as conducting a phase III enabling clinical trial for investigating IPLEX as a treatment for myotonic muscular dystrophy. Insmed also engages in various oncology programs, including INSM-18, an orally available small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF-1 and human epidermal growth factor receptor; and rhIGFBP-3, which is in early clinical development stage for the treatment of breast, prostate, liver, ovarian, and colon cancers. The company also provides Expanded Access Program in Italy to offer IPLEX to physicians for use in their patients with amyotrophic lateral sclerosis. It has a license to Pharmacia AB's portfolio of regulatory filings pertaining to rhIGF; and an agreement with NAPO Pharmaceuticals that gives NAPO the right to develop, manufacture, and commercialize masoprocal products for various indications relating to diabetes, cardiac disease, vascular disease, metabolic disease, and syndrome X.

Novogen Limited company was founded in 1994 and is headquartered in North Ryde, Australia. Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. In February, 2009, the Company announced that it focuses its activities on its oncology program. The Company operates subsidiary companies in 3 geographical areas: Australia, North America and Europe. The subsidiaries are involved in the selling and marketing of Novogen's consumer healthcare products. The Company’s product range includes Phenoxodiol, Triphendiol, NV-128, and GLYC-101. The Company’s subsidiaries include Novogen Laboratories Pty Ltd, Norvogen Pty Ltd, Glycotex, Inc. and Novogen BV.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.